Skip to main content
Equibles
TMDX logo

TMDX · TransMedics Group, Inc.

Track TMDX — free Ask ALVIS about TMDX
$76.13 -1.87 (-2.40%) At close · Jul 30
Market Cap
$2.63B
Shares
34.56M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$76.13 Open$76.34 Day$74.03–77.68 52W$60.11–156.00 Avg vol 30d999K Short int7.7M · 22.3% float · 9.5d Short vol54% Last earningsMay 5, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 5

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 17.1 · elevated Equity put/call 0.61
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −30%
      below
      Price vs 50-day avg +6%
      above
      RSI (14) 55
      neutral
      MACD trend Positive
      52-week position 17%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +12%
      trailing
      6-month return −41%
      trailing
      YTD return −37%
      this year
      Relative strength −51%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $72 › 200d $109 — 200d above 50d
      Institutional flow Distributing
      141 of 418 funds reported for Jun 30 · net -105.0K sh shares · +20 new
      Insider flow Distributing
      Net -$722.4K over 90 days · 100% sells
      Short interest Falling
      22.32% of float · ▼ -1.9% MoM · 9.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      418 holders — mid 3-yr range
      Squeeze score 78
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +37%
      Y/Y
      Gross margin 60%
      expanding
      EPS growth +382%
      Y/Y
      Free cash flow $133.6M
      Valuation P/E 17.4
      below peers
      Balance sheet $326.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 59%
      annualized · 1-yr
      Max drawdown −60%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 5, 2026
      Full year 2026 revenue · full year 2026 Initiated $727M – $757M
      prior FY $605.49M midpoint +22.5% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −30% Bearish
      Price vs 50-day avg
      +6% Bullish
      RSI (14)
      55 Neutral
      MACD trend
      Positive Bullish
      52-week position
      17% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $72 › 200d $109 — 200d above 50d
      Institutional flow Distributing
      141 of 418 funds reported for Jun 30 · net -105.0K sh shares · +20 new
      Insider flow Distributing
      Net -$722.4K over 90 days · 100% sells
      Short interest Falling
      22.32% of float · ▼ -1.9% MoM · 9.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      418 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $60 Now $76 · 17% 52-wk high $156
      vs 200-day avg -30% vs 50-day avg +6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      U.S. OCS cases 5,139 full year 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TMDX
      TransMedics Group, Inc.
      this stock
      		$2.63B -37.4% +37.1% 17.4 22.3%
      ABT
      Abbott Laboratories
      		 $183.95B -15.3% +5.7% 29.6 1.4%
      SYK
      Stryker Corp
      		 $133.42B -0.7% +11.2% 40.3 1.8%
      MDT
      Medtronic plc
      		 $109.71B -10.0% +8.4% 23.0 1.5%
      BSX
      Boston Scientific Corp
      		 $68.37B -51.8% +5.5% 19.3 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      404
      % held
      102.6%
      Reported
      141 of 418
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      382
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      7.7M
      Days to cover
      9.5d
      Change
      -150.4K sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Jul 30, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      1.1K
      Value
      $83.0K
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      52.5%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$722.4K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $605.5M
      Net income (FY)
      $190.3M
      EPS diluted
      $4.87
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      May 21, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $722.4K
      Shares
      9.6K
      Filed
      Jun 15, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TMDX +7.0% +12.2% -41.3% +14.6% -37.4%
      SPY +0.5% -0.6% +9.5% -0.7% +8.8%
      vs SPY +6.6% +12.8% -50.7% +15.3% -46.2%
      Key facts CIK 1756262 CUSIP 89377M109 13F (30d) 107 filings 107 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)